Idiopathic Short Stature - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/05/15
頁 數：43頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Idiopathic Short Stature - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Idiopathic Short Stature - Pipeline Review, H1 2014’, provides an overview of the Idiopathic Short Stature’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Idiopathic Short Stature, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Short Stature and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Idiopathic Short Stature
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Idiopathic Short Stature and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Idiopathic Short Stature products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Idiopathic Short Stature pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Idiopathic Short Stature
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Idiopathic Short Stature pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Idiopathic Short Stature - Pipeline Review, H1 2014’, provides an overview of the Idiopathic Short Stature’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Idiopathic Short Stature, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Short Stature and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Idiopathic Short Stature
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Idiopathic Short Stature and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Idiopathic Short Stature products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Idiopathic Short Stature pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Idiopathic Short Stature
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Idiopathic Short Stature pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Idiopathic Short Stature Overview 6
Therapeutics Development 7
Pipeline Products for Idiopathic Short Stature - Overview 7
Pipeline Products for Idiopathic Short Stature - Comparative Analysis 8
Idiopathic Short Stature - Therapeutics under Development by Companies 9
Idiopathic Short Stature - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Idiopathic Short Stature - Products under Development by Companies 14
Idiopathic Short Stature - Companies Involved in Therapeutics Development 15
JCR Pharmaceuticals Co., Ltd. 15
LG Life Sciences, Ltd. 16
Myungmoon pharmaceutical Co.,Ltd. 17
Braasch Biotech LLC 18
Bolder Biotechnology, Inc. 19
Dong-A Socio Holdings Co Ltd 20
Idiopathic Short Stature - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
somatropin - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
somatropin (recombinant) - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
somatropin SR - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
BBT-031 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Vaccine For Growth Hormone Deficiencies - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
MM-P02-01 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Idiopathic Short Stature - Recent Pipeline Updates 37
Idiopathic Short Stature - Dormant Projects 38
Idiopathic Short Stature - Discontinued Products 39
Idiopathic Short Stature - Product Development Milestones 40
Featured News & Press Releases 40
Mar 26, 2014: Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN In Very Young Children Born Small For Gestational Age 40
Aug 07, 2006: Pfizer Japan Obtains Approval for Genotropin Treatment for Adult Growth Hormone Deficiency. 40
Apr 11, 1997: Pharmacia & Upjohn Introduces Genotropin Pen 12 Growth Hormone Delivery Device -- A Preferred Injection System Among GHD Patients 41
Aug 28, 1995: Pharmacia receives FDA marketing clearance for Genotropin for treatment of growth hormone deficiency in children. 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43
List of Tables
Number of Products under Development for Idiopathic Short Stature, H1 2014 7
Number of Products under Development for Idiopathic Short Stature - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Idiopathic Short Stature - Pipeline by JCR Pharmaceuticals Co., Ltd., H1 2014 15
Idiopathic Short Stature - Pipeline by LG Life Sciences, Ltd., H1 2014 16
Idiopathic Short Stature - Pipeline by Myungmoon pharmaceutical Co.,Ltd., H1 2014 17
Idiopathic Short Stature - Pipeline by Braasch Biotech LLC, H1 2014 18
Idiopathic Short Stature - Pipeline by Bolder Biotechnology, Inc., H1 2014 19
Idiopathic Short Stature - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014 20
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Stage and Target, H1 2014 23
Number of Products by Stage and Mechanism of Action, H1 2014 25
Number of Products by Stage and Route of Administration, H1 2014 27
Number of Products by Stage and Molecule Type, H1 2014 29
Idiopathic Short Stature Therapeutics - Recent Pipeline Updates, H1 2014 37
Idiopathic Short Stature - Dormant Projects, H1 2014 38
Idiopathic Short Stature - Discontinued Products, H1 2014 39
List of Figures
Number of Products under Development for Idiopathic Short Stature, H1 2014 7
Number of Products under Development for Idiopathic Short Stature - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 13
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Top 10 Target, H1 2014 22
Number of Products by Stage and Top 10 Target, H1 2014 23
Number of Products by Top 10 Mechanism of Action, H1 2014 24
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 25
Number of Products by Top 10 Route of Administration, H1 2014 26
Number of Products by Stage and Top 10 Route of Administration, H1 2014 27
Number of Products by Top 10 Molecule Type, H1 2014 28
Number of Products by Stage and Top 10 Molecule Type, H1 2014 29
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Idiopathic Short Stature Overview 6
Therapeutics Development 7
Pipeline Products for Idiopathic Short Stature - Overview 7
Pipeline Products for Idiopathic Short Stature - Comparative Analysis 8
Idiopathic Short Stature - Therapeutics under Development by Companies 9
Idiopathic Short Stature - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Idiopathic Short Stature - Products under Development by Companies 14
Idiopathic Short Stature - Companies Involved in Therapeutics Development 15
JCR Pharmaceuticals Co., Ltd. 15
LG Life Sciences, Ltd. 16
Myungmoon pharmaceutical Co.,Ltd. 17
Braasch Biotech LLC 18
Bolder Biotechnology, Inc. 19
Dong-A Socio Holdings Co Ltd 20
Idiopathic Short Stature - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
somatropin - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
somatropin (recombinant) - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
somatropin SR - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
BBT-031 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Vaccine For Growth Hormone Deficiencies - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
MM-P02-01 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Idiopathic Short Stature - Recent Pipeline Updates 37
Idiopathic Short Stature - Dormant Projects 38
Idiopathic Short Stature - Discontinued Products 39
Idiopathic Short Stature - Product Development Milestones 40
Featured News & Press Releases 40
Mar 26, 2014: Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN In Very Young Children Born Small For Gestational Age 40
Aug 07, 2006: Pfizer Japan Obtains Approval for Genotropin Treatment for Adult Growth Hormone Deficiency. 40
Apr 11, 1997: Pharmacia & Upjohn Introduces Genotropin Pen 12 Growth Hormone Delivery Device -- A Preferred Injection System Among GHD Patients 41
Aug 28, 1995: Pharmacia receives FDA marketing clearance for Genotropin for treatment of growth hormone deficiency in children. 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43
List of Tables
Number of Products under Development for Idiopathic Short Stature, H1 2014 7
Number of Products under Development for Idiopathic Short Stature - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Idiopathic Short Stature - Pipeline by JCR Pharmaceuticals Co., Ltd., H1 2014 15
Idiopathic Short Stature - Pipeline by LG Life Sciences, Ltd., H1 2014 16
Idiopathic Short Stature - Pipeline by Myungmoon pharmaceutical Co.,Ltd., H1 2014 17
Idiopathic Short Stature - Pipeline by Braasch Biotech LLC, H1 2014 18
Idiopathic Short Stature - Pipeline by Bolder Biotechnology, Inc., H1 2014 19
Idiopathic Short Stature - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014 20
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Stage and Target, H1 2014 23
Number of Products by Stage and Mechanism of Action, H1 2014 25
Number of Products by Stage and Route of Administration, H1 2014 27
Number of Products by Stage and Molecule Type, H1 2014 29
Idiopathic Short Stature Therapeutics - Recent Pipeline Updates, H1 2014 37
Idiopathic Short Stature - Dormant Projects, H1 2014 38
Idiopathic Short Stature - Discontinued Products, H1 2014 39
List of Figures
Number of Products under Development for Idiopathic Short Stature, H1 2014 7
Number of Products under Development for Idiopathic Short Stature - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 13
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Top 10 Target, H1 2014 22
Number of Products by Stage and Top 10 Target, H1 2014 23
Number of Products by Top 10 Mechanism of Action, H1 2014 24
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 25
Number of Products by Top 10 Route of Administration, H1 2014 26
Number of Products by Stage and Top 10 Route of Administration, H1 2014 27
Number of Products by Top 10 Molecule Type, H1 2014 28
Number of Products by Stage and Top 10 Molecule Type, H1 2014 29
